We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Marks Electrical Group Plc | LSE:MRK | London | Ordinary Share | GB00BM8Q5G47 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 53.75 | 52.50 | 55.00 | 53.75 | 53.75 | 53.75 | 4,577 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Elec Appliance,tv,radio-whsl | 114.26M | 427k | 0.0041 | 131.10 | 56.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/5/2007 06:18 | Actelion share split to take effect Wednesday ZURICH (Thomson Financial) - Actelion said the previously announced one-to-five split in shares of Actelion will take effect on Wednesday, 6 June 2007. The group's shareholders approved this stock split at their Annual General Meeting on, 4 May 2007. johanna.treeck@thoms jmt/jfr | ariane | |
04/5/2007 16:58 | Merck & CO Merck 'disappointed' at Brazilian decision to bypass HIV drug patent LONDON (Thomson Financial) - Merck & Co said it was "profoundly disappointed" by the decision of the Brazilian government to bypass the patent protecting the company's HIV drug Efavirenz. "Merck is profoundly disappointed by the decision of the Government of Brazil (GOB) to issue a compulsory license for STOCRIN(TM) (Efavirenz), which would break Merck & Co, Inc.'s patent and make it possible for Efavirenz to be produced by a generic manufacturer," the company said in a statement. Brazil and the Whitehouse Station, N.J.-based drug maker have been in negotiations for a lower-priced version of the drug. The country asked Merck to reduce the price of the drug from 1.57 usd a pill to 65 cents but Merck had offered a 30 pct discount on Efavirenz at 1.10 usd. Now, Brazil plans to issue a compulsory license under World Trade Organization regulations to begin making or buying cheaper versions of the drug. Merck said it had negotiated in "good faith" and was still "flexible and committed" to reaching a mutually-acceptable agreement. "This decision by the GOB will have a negative impact on Brazil's reputation as an industrialized country seeking to attract inward investment, and thus its ability to build world-class research and development," Merck warned. tf.TFN-Europe_newsde jlc | waldron | |
03/5/2007 13:39 | Actavis bid for Merck KGaA generics ops less than asking price - source UPDATE (Updating that Teva and joint private equity bid from Apax Partners and Bain Capital still in running for Merck KGaA's generics ops) FRANKFURT (Thomson Financial) - Generic drugs giant Actavis had offered Merck KGaA a sum a few hundred mln eur lower than the sum being offered by rival bidders for the company's generics operations, before last night being "advised" by the pharmaceutical giant to pull out of the bidding process, a source close to the situation told Thomson Financial News. The source said that estimations that rival bidders were offering in the region of between 4-5 bln eur were not incorrect. "The gap between what Actavis was willing to pay and what Merck is expecting was estimated to be too large, and would have meant stretching the company significantly. He added: "We are not talking about a billion or anything like that, we are talking about a difference of a few hundred million euros. "It seems that Merck is looking to create value rather than synergy potentials." Rumours began circulating in financial circles today that Actavis had been "kicked out" of the bidding process, due to its inability to meet conditions set by Merck. "I do not know why these rumours were sparked, but they are completely untrue. "Actavis has the financial means to undertake this acquisition, but decided simply that the expected price was too high," clarified the source. Actavis is now planning to focus on smaller acquisitions in the region of up to a few hundred mln eur, added the source. In particular, it is hoping to expand in southern Europe, Latin America and Asia. Actavis said earlier today that it has the financial means for major acquisition opportunities -- including that of Merck's generics operations -- and added that it will continue to evaluate other acquisition opportunities. Sources today said that two further parties -- Israel's Teva Pharmaceuticals and a joint private equity offer from Apax Partners and Bain Capital -- are now battling it out in the war for Merck's generic operations. krysia.diver@thomson kd//cmr | waldron | |
01/5/2007 06:40 | Merck Kgaa Bids for Merck generics arm rise above 4 bln eur - report LONDON (Thomson Financial) - Aggressive competition for the generic drugs arm of Merck KGaA of Germany pushed offers beyond 4 bln eur at the close of a revised round of bids yesterday, the Financial Times reported, citing a source familiar with the process. Four rivals - Actavis of Iceland, Teva of Israel, Mylan of the US and a joint private equity offer from Apax Partners and Bain Capital - all stayed in the auction after completing due diligence in recent weeks, the FT said. However, a definitive decision to proceed with the sale has yet to be made, and one person with knowledge of the process said yesterday that the financial information made available to the bidders remained limited and a further final round could still be required in the weeks ahead. Michael Roehmer, the outgoing chief executive of Merck, said at the company's annual meeting last Friday that no decision had yet been made on whether to proceed with the sale. He stressed that the disposal would be "the right step for the future of the company", as Merck concentrated on its remaining branded medicine, consumer healthcare and chemicals divisions. tf.TFN-Europe_newsde jlw | waldron | |
27/4/2007 15:40 | Merck & CO FDA rejects Merck's Vioxx successor TRENTON, N.J. (AP) - The Food and Drug Administration rejected Merck & Co.'s request to market a successor to its withdrawn arthritis drug Vioxx in the United States, the drugmaker said Friday. The move was widely expected, after a panel of FDA advisers two weeks ago voted 20-1 against approving the drug, Arcoxia. Arcoxia is in the same class of drugs as Vioxx, which has become a poster child for drug safety problems. Merck pulled Vioxx from the market in September 2004 after research showed it doubles risk of heart attacks and strokes. That triggered an avalanche of lawsuits -- more than 27,000 so far -- and a nosedive for Merck's stock price, which has since bounced back. Despite the safety concerns in the United States, Arcoxia is on sale in 63 other countries, and Merck officials said as recently as Tuesday that they intend to keep working to get it on the U.S. market. Arcoxia had been poised for approval until Vioxx was pulled from the market. Two months later, the FDA issued what's called an "approvable" letter, saying it could approve Arcoxia, but only if Merck provided further safety and efficacy information for the drug. Merck has since produced results from further studies of Arcoxia, but doctors questioned those results because Merck compared Arcoxia in its tests to another painkiller that has elevated risk of heart attacks and strokes. Peter S. Kim, president of Merck Research Laboratories, told company shareholders at their annual meeting Tuesday that "there is more long-term safety data on Arcoxia than" other drugs in the same class and traditional anti-inflammatory medicines. "We are committed to working with the FDA to determine the best approach" to get it on the U.S. market, Kim said. A Merck spokeswoman did not immediately return a call seeking comment Friday morning. Merck shares sank 55 cents, or 1 percent, to $51.88 in morning trading on the New York Stock Exchange. They are still trading near their 52-week high of $52.63. Their low over the past year was $32.75. | waldron | |
24/4/2007 15:11 | FDA expected to OK Pfizer HIV drug WASHINGTON (AP) - Analysts expect Pfizer to win approval for a first-of-a-kind drug to treat HIV despite safety concerns raised by government regulators ahead of a Tuesday meeting. A panel of experts meets in Rockville, Md., to advise the Food and Drug Administration on whether to approve Pfizer's maraviroc to fight HIV. If approved it would be the first in a new class of treatments that block HIV from entering white blood cells through a pathway present in some patients that carry the virus. Although FDA reviewers noted a slight increase in liver problems among patients taking the drug, analysts say the drug's effectiveness should outweigh any safety concerns. "While more controversial than we had originally expected, we believe the favorable risk-benefit profile of maraviroc will lead to a panel recommendation for approval," Piper Jaffray analyst Thomas Weil said in a research note. FDA is not obligated to follow the recommendation of its panel, but it usually does. The agency is scheduled to make its final decision on maraviroc in June. Roughly 1 million people in the U.S. are HIV positive, but only a subset of that group would be able to take Pfizer's pill, which will initially be labeled for patients who have stopped responding to drugs already on the market. "Out of the gate, I would expect maraviroc to be cubby-holed into the salvage population of patients who have already failed a number of treatments and have limited treatment options," said Dr. Jacob Lalezari, who was lead investigator on Pfizer's study of the drug. With its proposed labeling, maraviroc is expected to post sales of $25 million in 2007 and $375 million by 2010, according to Thomas Weisel Partners analyst Peter Lawson. By comparison, Gilead Science's top-selling HIV drug, Viread, posted $689 million in sales last year. Maraviroc's indication could eventually be expanded to include patients with early stage HIV, according to Lalezari, because the pathway the drug uses to block HIV is more common in these patients. Only about half of late stage HIV patients have the pathway. By the time Pfizer is ready to market maraviroc as an initial treatment for HIV, though, several competitors could have similar drugs on the market. Pharmaceutical giant Schering Plough Corp. expects to begin final trials of its own HIV-blocking drug before the end of the year. Also, Incyte Corp. is working on a similar medicine in a once-a-day dosage, which could be a competitive advantage over Pfizer's twice-a-day pill. "We think our compound looks very good and having the potential to be the best-in-class makes it worthwhile for us to take the time to focus on development," said company spokeswoman Pamela Murphy. Wilmington, Del.-based Incyte expects to enter late-stage trials in 2009. Perhaps an even bigger potential competitor for maraviroc is an experimental HIV drug which Merck & Co. Inc. is preparing to submit to FDA. Studies released last month showed Merck's Isentress effectively controls HIV while causing virtually no side effects. Because Merck's and Pfizer's drugs fight HIV in different ways, AIDS researcher Dr. Albrecht Helmut said they could potentially be used in combination. "If they play well together they could be used together, but that remains to be seen" said Helmut, who is a professor at the University of South Carolina. "So there's a chance for collaboration here but also for competition as the two companies try to be the first to get to these patients who have already failed other treatments." Shares of Pfizer Inc. rose 2 cents Tuesday to $26.37 in morning trading on the New York Stock Exchange. | waldron | |
21/4/2007 05:46 | Date : 21/04/2007 @ 00:15 Source : AFX Merck & CO Ruling puts Texas Vioxx lawsuits on hold HOUSTON (AP) - More than 1,000 personal injury lawsuits filed in Texas over the once-popular pain medication Vioxx were put on hold Friday after a judge ruled the drug's manufacturer had given adequate warnings about the drug. State District Judge Randy Wilson, based in Harris County, granted a motion by Merck & Co. Inc., the drug's manufacturer, to dismiss part of a lawsuit filed by Ruby Ledbetter. Merck's attorneys argued a 2003 Texas law prevents Ledbetter from claiming she wasn't properly warned about Vioxx. The law, passed as part of tort reform efforts, says a drug manufacturer is not liable in allegations it failed to provide sufficient warnings about its product if the drug in question came with warnings approved by the Food and Drug Administration. Friday's ruling put Ledbetter's case on hold. But Travis Sales, one of Merck's attorneys, said Wilson had previously told lawyers in the case that such a decision would put all Texas cases on hold until appeals courts rule on the issue. Wilson is presiding over all Vioxx lawsuits filed in Texas. "The court got it right," Sales said. "It goes to the heart of what Merck has always said. Merck gave proper information to the FDA and the FDA made proper labeling information based on what was there at the time." Tommy Fibich, one of Ledbetter's attorneys, did not immediately return a telephone call seeking comment Friday. Vioxx, an arthritis pain reliever, was pulled from the market in September 2004, when a study showed it could double the risk of heart attack or stroke if taken more than 18 months. Whitehouse Station, N.J.-based Merck said it now faces 27,250 personal injury lawsuits over Vioxx, including 45,700 plaintiff groups. The company is sticking by its plan of defending each of thousands of claims over Vioxx rather than settling the suits. | ariane | |
17/4/2007 10:56 | Actavis, Torrent seen as top contenders for Merck KGaA's generic ops - report FRANKFURT (Thomson Financial) - Iceland's Actavis Group and India's Torrent Pharmaceuticals Ltd could compete in a head-to-head race to win Merck KGaA's generic operations, which according to financial circles could fetch more than 6 bln usd, reported the Times of India, citing sources. Rival contender Teva Pharmaceuticals Industries Ltd could be put off by the high price tag, as it already has a strong presence in markets where Merck operates - including the US, Canada, Europe and Australia, added the report. krysia.diver@thomson kd/lam | ariane | |
13/4/2007 18:56 | Sanofi-Aventis/Merck in 200 mln eur upgrade of French bird flu vaccine plant EVREUX, France (Thomson Financial) - Sanofi-Aventis and Merck & Co Inc joint venture Sanofi-Pasteur said it is to invest 200 mln eur in order to increase production capacity at its Val-de-Reuil plant in Northern France, which produces the group's bird flu vaccines. The upgrade, which will raise output capacity of yellow fever and polio as well as flu vaccines, is expected to be complete in 2009. The factory produced 120 mln doses in 2006 and the new annual capacity will be 210 mln, a spokesman told Agence France-Presse. The Val-de-Reuil plant manufactured 1.4 mln doses of the H5N1 bird flu vaccine in 2006 at the government's request and Sanofi-Pasteur has pledged it can quickly supply 28 mln doses in the event of an outbreak. tf.TFN-Europe_newsde afp/mrg/amb | ariane | |
12/4/2007 16:34 | Date : 12/04/2007 @ 17:29 Source : AFX Merck & CO FDA scientist blasts proposed pain drug WASHINGTON (AP) - A painkiller proposed as a successor to Vioxx may substantially increase the risk of stroke and heart attack and is no more effective for pain relief than other drugs of the same class, a federal drug safety expert said Thursday. Safety studies done on the proposed drug, Arcoxia, are neither adequate nor reasonable to support its approval, Food and Drug Administration scientist Dr. David Graham told a panel of agency advisers. Graham has been a leading critic of Vioxx, also known as rofecoxib. "What you're talking about is a potential public health disaster," Graham said of Arcoxia. "We could have a replay of what we had with rofecoxib." Merck & Co. Inc. seeks FDA approval to sell Arcoxia, also known as etoricoxib, to treat the signs and symptoms of osteoarthritis. The Whitehouse Station, N.J., company withdrew Vioxx in 2004, after it was linked to a higher risk of stroke and heart attack when compared to dummy pills. A Merck official said the company has "comprehensively characterized the safety and efficacy profile" of Arcoxia. The prescription drug is the first of its class to seek FDA approval since Merck withdrew Vioxx. "We at Merck believe etoricoxib represents a valuable treatment option for patients with osteoarthritis. We would like to emphasize there is more long-term safety data ... for etoricoxib that any other NSAID," said Peter Kim, president of Merck's research laboratories. An estimated 21 million Americans suffer from osteoarthritis. NSAIDs, or nonsteroidal anti-inflammatory drugs, are a common treatment. Arcoxia and Vioxx are types of NSAIDs called Cox-2 inhibitors, developed to be gentler on the stomach. The FDA said this week that new NSAIDs that increase the risk of stroke and heart attack shouldn't be approved if safer alternatives are available. The FDA convened a panel of expert advisers to weigh whether to recommend the agency approve Arcoxia. The FDA isn't required to follow the advice of its advisory committees but usually does. Merck hopes FDA will make a final decision by month's end. | ariane | |
10/4/2007 16:11 | Merck & CO FDA may OK Arcoxia, a Vioxx follow-up (AP) - Merck & Co. Inc. shares showed little reaction Tuesday to the release of government documents reviewing the pain-relieving drug Arcoxia. The Food and Drug Administration posted the Arcoxia review to its Web site ahead of a Thursday meeting at which non-agency arthritis experts are expected to vote on whether the drug should be approved. The agency is not required to follow the panel's recommendation, though it often does. Arcoxia would be the first in the same class of drugs as Vioxx and Bextra to gain U.S. approval since those drugs were pulled from the market after showing links to heart attack and stroke in 2004 and 2005. The prospect of FDA approval of a drug similar to Vioxx, which attained blockbuster status in its five years on the market, has attracted scrutiny from patients and physicians. But Wall Street seems unconcerned with the drug's potential on speculation that safety concerns would limit sales. "Our position has been that it won't get approved, but even if it does, it will hardly make an impact," said Kate Hohenberg, an analyst with pharmaceutical research firm Decision Resources. Arcoxia is part of a class of drugs called cox-2 inhibitors, thought to be gentler on the stomach than over-the-counter medicines such as Tylenol and Advil. Pfizer, which made Bextra, still sells Celebrex, another cox-2 drug. In its summary, FDA staff note that while Arcoxia had blood-clotting risks in line with another commonly prescribed pain reliever, it showed higher incidence of hypertension-related heart problems when compared with the same drug. Hohenberg estimated Arcoxia sales could be limited by restrictive labeling that Celebrex does not have. In Europe, for example, Arcoxia was approved with a specific warning label indicating that it should not be used by patients with hypertension. "Merck has not revealed why anyone would be compelled to use its drug over the one already available," said Hohenberg. Whitehouse Station, N.J.-based Merck also could find Arcoxia competing against cheaper generic versions of Celebrex after that drug loses patent protection, which could happen as early as 2013. And Merck's FDA application for Arcoxia seeks approval for use only in patients with osteoarthritis. While the osteoarthritic population in the United States is significant at 21 million, it is much smaller than the market had been for Vioxx, which was approved for osteoarthritis, rheumatoid arthritis and a variety of other chronic pain conditions. Merck did not break out potential sales from Arcoxia in its 2007 guidance, instead lumping the product in with other drugs that are not considered major franchises. Together the group of more than a dozen products are expected to bring in sales of $5.2 to $5.6 billion for the year. By comparison, Merck's top-selling allergy medication Singulair is expected to generate revenues between $3.7 and $4 billion next year. Still, Dr. Patience White of the Arthritis Foundation says Arcoxia is likely to find a niche among arthritis sufferers who do not respond to more traditional pain relievers. "There's a percentage of patients out there who recognize that they face a greater risk from the disability associated with their pain than the reported risk of the drug," said White, who is chief public health officer for the not-for-profit group. Shares of Merck & Co. rose 5 cents Tuesday to $45.70 in morning trading on the New York Stock Exchange. Pfizer rose 3 cents to $26.02, also on the NYSE. | ariane | |
27/3/2007 16:19 | Merck & CO Jurors side with Merck in Vioxx trial EDWARDSVILLE, Ill. (AP) - Jurors in the Midwest's first trial over the once-blockbuster painkiller Vioxx on Tuesday cleared the drug's maker in the 2003 deadly heart attack of a 52-year-old woman. A Madison County court jury deliberated over two days before siding with Merck & Co., which had argued that Patty Schwaller's weight and other health issues might have posed risks that better explain her collapse and sudden death. Schwaller had taken Vioxx for about 20 months. Her husband claimed that Vioxx contributed to his wife's death and that Merck failed to sufficiently warn consumers that the drug increased the risk of cardiovascular problems. The victory was Merck's 10th in 15 cases that have been tried in the mushrooming litigation over the drug Merck pulled off the market in 2004 after its research showed it increased the risk of heart attacks and strokes. During the monthlong trial in this St. Louis suburb, where large jury awards favoring plaintiffs earned Madison County the label by some as a "judicial hellhole," Merck lawyers insisted that Patty Schwaller had several risk factors for heart disease, including obesity, diabetes, high blood pressure and a sedentary lifestyle. The 5-foot-2 woman's weight fluctuated between 250 and 300 pounds for roughly two decades before her death, attorneys have acknowledged. But attorneys for Schwaller's widower, Frank Schwaller, pressed that the woman had no heart attacks, strokes or symptoms of congestive heart disease before her fatal collapse, fueling their belief that Vioxx contributed to her demise. Mikal Watts, a Schwaller attorney told jurors Monday that Merck pushed consumers like Patty Schwaller "over the cliff" by failing to adequately study Vioxx's possible side-effects on people at risk of heart disease. Watts said Merck publicly downplayed worries by outside researchers that Vioxx could put users at greater risk of heart attacks or strokes. Top Merck executives "kept cutting the data until it told them what they wanted it to say," Watts insisted. Watts argued that Merck put profits ahead of patient safety by allegedly rushing Vioxx to market. The drug became the company's No. 2 drug, generating more than $11 billion in sales from May 1999 through September 2004, according to regulatory filings and other information from the company, based in Whitehouse Station, N.J. "I'm not against companies making money, but not at the expense of their patients," Watts told jurors. But Dan Ball, an attorney for Merck, accused the Schwaller family's attorney of cherry-picking and misrepresenting Merck e-mails to "assault" the reputation of a company he said was dedicated to making lives better. Ball said Vioxx labels in 1999 and 2002 -- well before Patty Schwaller's death -- urged caution among users with cardiovascular risks including hypertension. He urged jurors to look to Schwaller's health troubles in deciding what caused her death. "A person with these kinds of issues sometimes can die early, tragically, and medicine doesn't have a doggone thing to do with it," Ball told jurors. "Let's try not to forget the undisputed fact that most people who took this medicine had no issues at all." The trial has been closely watched in Madison County, which has gained national notoriety as a place where lawyers from across the country file cases involving everything from asbestos exposure to medical malpractice, hoping for big payouts. Merck has been deluged with more than 27,000 personal injury lawsuits and another 265 potential class-action lawsuits alleging harm from Vioxx. The company has reserved $1.64 billion in its Vioxx legal defense fund, saying it plans to fight each lawsuit. On March 12, jurors in Atlantic City, N.J., found that Vioxx contributed to an Idaho postal worker's 2001 heart attack, reversing the verdict in the man's first trial and hitting Merck with a total of $47.5 million in damages. If the verdict and damage amounts are upheld on appeal, it could be the biggest hit to Merck so far. In the only Vioxx case with a larger verdict -- $51 million awarded last August to Gerald Barnett of Myrtle Beach, S.C. -- U.S. District Judge Eldon E. Fallon in New Orleans ordered a new trial on damage award, calling the total "grossly excessive." A New Jersey Supreme Court panel also is considering whether to allow health insurers and union health plans to sue Merck jointly to recover money they paid for Vioxx prescriptions -- a lawsuit potentially worth more than $15 billion. A New Jersey state judge granted that lawsuit class-action status in mid-2005, and a state appellate court ruled last year that the nationwide suit could go forward. Merck is appealing. | waldron | |
27/3/2007 04:52 | Merck & CO Deliberations continue in Vioxx trial EDWARDSVILLE, Ill. (AP) - Jurors at the first Vioxx trial in the Midwest have begun weighing whether poor health or the once-blockbuster painkiller is to blame for a 52-year-old woman's fatal 2003 heart attack. Deliberations that lasted nearly 5 1/2 hours Monday night were to continue Tuesday morning in Madison County. Attorneys for Patty Schwaller's widower urged jurors during closing arguments to sock Merck & Co. in the pocketbook, saying the company failed to sufficiently warn consumers that the drug increased the risk of cardiovascular problems. Schwaller took Vioxx for about 20 months before suddenly collapsing in her Granite City home near St. Louis in August 2003 and dying. Merck pulled the drug off the market in 2004 after its research showed it increased the risk of heart attacks and strokes. Schwaller "shall not have died in vain," Mikal Watts, an attorney for the family, told jurors. Citing the company's own internal e-mails, Watts said Merck failed to adequately study Vioxx's possible side-effects on people at risk of heart disease and publicly downplayed worries by outside researchers that Vioxx could put users at greater risk of heart attacks or strokes. "I'm not against companies making money, but not at the expense of their patients," Watts said. Top Merck executives "kept cutting the data until it told them what they wanted it to say." Vioxx, once Merck's No. 2 drug, generated sales exceeding $11 billion from May 1999 through September 2004, according to regulatory filings and other information from the company, based in Whitehouse Station, N.J. Schwaller's family has claimed that the 5-foot-2 woman -- whose weight fluctuated between 250 and 300 pounds for at least two decades -- had no heart attacks, strokes or symptoms of congestive heart disease before her fatal collapse. Merck, Watts insisted, pushed consumers like Schwaller "over the cliff" by putting profits over patient safety. But Merck attorney Dan Ball accused the Schwaller family's attorney of cherry-picking and misrepresenting Merck e-mails to "assault" the reputation of a company he said was dedicated to making lives better. Ball said Vioxx labels in 1999 and 2002 -- well before Patty Schwaller's death -- urged caution among users with cardiovascular risks including hypertension, but he suggested Schwaller's obesity, diabetes, high blood pressure and sedentary lifestyle might have posed risks that better explain her collapse and sudden death. "A person with these kinds of issues sometimes can die early, tragically, and medicine doesn't have a doggone thing to do with it," Ball said. "Let's try not to forget the undisputed fact that most people who took this medicine had no issues at all." Still, he noted, "all medicines have risks, and sometimes bad things happen." The trial has been closely watched in Madison County, which has gained national notoriety as a place where lawyers from across the country file cases involving everything from asbestos exposure to medical malpractice, hoping for big payouts. Merck has been deluged with more than 27,000 personal injury lawsuits and another 265 potential class-action lawsuits alleging harm from Vioxx. The company has reserved $1.64 billion in its Vioxx legal defense fund, saying it plans to fight each lawsuit. On March 12, jurors in Atlantic City, N.J., found that Vioxx contributed to an Idaho postal worker's 2001 heart attack, reversing the verdict in the man's first trial and hitting Merck with a total of $47.5 million in damages. If the verdict and damage amounts are upheld, it could be the biggest hit to Merck so far. In the only Vioxx case with a larger verdict -- $51 million awarded last August to Gerald Barnett of Myrtle Beach, S.C. -- U.S. District Judge Eldon E. Fallon in New Orleans ordered a new trial on damage award, calling the total "grossly excessive." A New Jersey Supreme Court panel also is considering whether to allow health insurers and union health plans to sue Merck jointly to recover money they paid for Vioxx prescriptions -- a lawsuit potentially worth more than $15 billion. A New Jersey state judge granted that lawsuit class-action status in mid-2005, and a state appellate court ruled last year that the nationwide suit could go forward. Merck is appealing. | waldron | |
26/3/2007 16:23 | Merck, Roche Cholesterol Drugs May Be Hurt by Pfizer's Failure By Shannon Pettypiece March 26 (Bloomberg) -- Merck & Co. and Roche Holding AG's efforts to develop the next generation of cholesterol drugs may be derailed by results showing Pfizer Inc.'s attempt proved both deadly and ineffective. Pfizer's experimental drug torcetrapib, which cost about $1 billion to develop, doesn't reduce fatty plaque in arteries and raises blood pressure, according to two studies released today at the American College of Cardiology meeting in New Orleans. Earlier findings showed the drug increased death rates. The results have set off a debate among doctors on whether torcetrapib's problems are unique to its chemical makeup, or if they'll carry over to similar pills in development. Torcetrapib was furthest along in a new class of drugs that analysts said may have annual sales of as much as $20 billion. The drugs block a protein that raises levels of HDL, or good cholesterol, which sweeps fatty plaque from arteries. ``What happened will be the source of an incredibly intense discussion,'' said Steven Nissen, the lead author of one of the studies and chairman of cardiology at the Cleveland Clinic. `` I don't want to kill a class that might work, but the bar is just a whole lot higher after seeing these data.'' The shares of Whitehouse Station, New Jersey-based Merck fell 5 cents to $44.40 at 9:57 a.m. in New York Stock Exchange trading. The shares of Roche, based in Basel, Switzerland, increased 60 centimes, or less than a percent, to 219.90 Swiss francs. Testing Stages Merck is entering the finals stages of testing on a drug similar to torcetrapib and Roche is in the second of three phases of testing for its drug. Pfizer also finished phase one testing last year on two other drugs that work like torcetrapib. Merck and Roche said earlier this year they would be closely monitoring the data Pfizer released on its failed drug. All three companies' drugs work by blocking the cholesterol ester transfer protein, or CETP, which converts good cholesterol into the bad form. Nissen said nearly every major drug company is studying the class of drugs, though only Pfizer, Merck and Roche have publicly acknowledged it. Further research is needed before experts can determine whether the entire class of drugs is flawed, Nissen said. Those studies should be slower and more methodical than Pfizer's, meaning higher costs and a longer wait to market the drug. ``I don't think we can kill the class until we test a clean drug,'' Nissen said. ```I think someone will test the waters there and we'll help them do that, but I'm equally concerned about protecting our patients who enroll in clinical trials. This is a very, very challenging situation.'' Risk, Cost The question for drugmakers is whether the risk and cost of pursuing this area of research is worth the reward considering Pfizer's failed attempt. In December, Pfizer halted development of torcetrapib combined with its cholesterol pill Lipitor after a study showed the drug increased death rates by 60 percent compared with Lipitor alone. ``If imaging results on torcetrapib are indeterminate, these companies will have to do some serious `soul searching' to determine whether they want to continue spending time and money developing their own respective CETP inhibitors,'' said Prudential Equity Group Inc. analyst Tim Anderson in a note to clients last week prior to the release of the torcetrapib data. One thing that may distinguish the Merck and Roche drugs is that unlike torcetrapib neither has shown in early testing to increase blood pressure during short-term trials, the drugs' makers said. Torcetrapib increased blood pressure an average of 4.6 millimeters, which is more than previously expected, according to one study presented today. Raising blood pressure may outweigh the benefits of increasing HDL or be a signal for the underlying problem causing the drug to not work, he said. Months Vs. Weeks The blood pressure effect didn't show up immediately and got worse over months. Merck has only studied its drug in patients for eight weeks at a time. The studies' authors should have provided an analysis of whether they believe the blood pressure risk was linked to the drugs safety and ineffectiveness, said Jim Stein, head of preventative cardiology at the University of Wisconsin. He called that failure ``a real weakness.'' Pfizer said it hopes to determine by the end of the year whether the torcetrapib problems are unique to the drug or its mechanism of action, said Pfizer head of world wide drug development Michael Berelowitz in an interview. -- Editor: Gale. To contact the reporter on this story: Shannon Pettypiece in New York at spettypiece@bloomber | waldron | |
26/3/2007 13:21 | Merck & CO Merck's Januvia diabetes drug wins European Union approval LONDON (AFX) - Merck & Co., Inc said its once-a-day oral treatment for patients with type 2 diabetes, Januvia, has been granted a license from the European Commission. The company said that Januvia is the first and only medication in a new class of drugs known as dipeptidyl peptidase-4 inhibitors -- which enhance the body's own ability to lower blood sugar when it is elevated -- to be adopted by the European Commission. The adoption applies to all of the 27 countries that are members of the EU, including the United Kingdom, Germany, France, Italy and Spain, as well as Norway and Iceland: Januvia will be launched shortly in the EU. Merck said Januvia is now approved for use in 42 countries around the world including Mexico, the United States, and the Philippines. newsdesk@afxnews.com rw | waldron | |
26/3/2007 13:21 | Merck & CO Merck, Schering-Plough to develop new cholesterol-lowering medicine LONDON (AFX) - Merck & Co Inc and joint-venture partner Schering-Plough Corp have agreed to develop a new cholesterol-lowering medicine that will combine their existing ezetimibe and atorvastatin products. The combined medicine, to be produced by the two companies' Merck/Schering-Ploug as patent exclusivity for atorvastatin expires both in the US and internationally. newsdesk@afxnews.com ms1 | waldron |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions